Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415446 | 0.91 | NPY5R (0.40) | BRD4ATAD2ALDH1A1LMNATSHR | |
| SCHEMBL17865687 | 0.89 | BRD4 (0.40) | BRD4ATAD2PLGPLATCCNT1 | |
| SCHEMBL17865657 | 0.85 | HRH4 (0.40) | BRD4ATAD2HRH4CCNT1CDK9 | |
| SCHEMBL17865721 | 0.80 | CDK9 (0.39) | HRH4CCNT1CDK9HDAC8PIM1 | |
| SCHEMBL17865716 | 0.74 | CDK9 (0.38) | BRD4ATAD2PLGCCNT1CDK9 | |
| SCHEMBL17911123 | 0.73 | LMNA (0.34) | BRD4ATAD2LMNA | |
| SCHEMBL17865536 | 0.73 | HRH4 (0.53) | HRH4 | |
| SCHEMBL17865504 | 0.73 | PIN1 (0.41) | BRD4ATAD2HRH4ALDH1A1LMNA | |
| SCHEMBL2999762 | 0.72 | BRD4 (0.48) | BRD4ATAD2ALDH1A1LMNATSHR | |
| SCHEMBL3005238 | 0.72 | NPY5R (0.45) | LMNANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | claimed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | BRD4 2391/4885ATAD2 3099/4885HRH4 633/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | BRD4 2061/4885ATAD2 2883/4885HRH4 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.